Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

2,124.00p
   
  • Change Today:
      14.00p
  • 52 Week High: 3,170.00
  • 52 Week Low: 1,966.00
  • Currency: UK Pounds
  • Shares Issued: 66.54m
  • Volume: 324,732
  • Market Cap: £1,413.30m
  • RiskGrade: 128
  • Beta: 0.01

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (£m) Pre-tax (£m) EPS Dividend
31-Dec-25 Interim 335.60 39.50 60.80p 11.20p

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-21 574.30 55.80 100.90p 49.2 1.6 +30% 32.00p 0.6%
30-Jun-22 593.40 48.40 82.70p 30.3 n/a -18% 32.00p 1.3%
30-Jun-23 689.70 39.40 84.80p 25.5 12.8 +2% 32.00p 1.5%
30-Jun-24 668.80 5.50 65.50p 25.2 n/a -23% 32.00p 1.9%
30-Jun-25 672.80 28.50 81.80p 25.0 1.0 +25% 32.00p 1.6%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-26 676.01 93.21 104.89p 20.1 0.7 +28% 34.60p 0.0%
30-Jun-27 686.30 88.90 103.60p 20.4 n/a -1% 35.79p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 49.16 25.00 31.04 0.84

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price 2,124.00p
Change Today 14.00p
% Change 0.66 %
52 Week High 3,170.00
52 Week Low 1,966.00
Volume 324,732
Shares Issued 66.54m
Market Cap £1,413.30m
Beta 0.01
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.49% below the market average92.49% below the market average92.49% below the market average92.49% below the market average92.49% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
78.22% above the market average78.22% above the market average78.22% above the market average78.22% above the market average78.22% above the market average
90.91% above the sector average90.91% above the sector average90.91% above the sector average90.91% above the sector average90.91% above the sector average
Income
98.6% below the market average98.6% below the market average98.6% below the market average98.6% below the market average98.6% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
91.76% below the market average91.76% below the market average91.76% below the market average91.76% below the market average91.76% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 5
Buy 1
Neutral 1
Sell 1
Strong Sell 0
Total 8
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 05-Mar-26 06-Nov-25
Paid 27-Mar-26 05-Dec-25
Amount 11.20p 21.70p

Trades for 15-Jul-2026

Time Volume / Share Price
15:13 1 @ 2,122.66p
15:13 1 @ 2,123.12p
15:12 44 @ 2,124.00p
15:12 16 @ 2,124.00p
15:11 89 @ 2,122.00p

Genus Key Personnel

CEO Jorgen Kokke
CFO Andy Russell

Top of Page